Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
But the timeline for a US green light is less clear, and the group has a cash crisis.
First-in-human trial initiations include Biocytogen's DM002 and Day One's DAY301.
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
Clinical expansion shows regulators getting comfortable with in vivo-generated cell therapy.
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
The private group taps DualityBio for an EGFR x HER3 ADC.
